Albert Rodriguez to present on user-centered design for MedTech devices and Christopher Gates to host a presentation on aligning FDA expectations and EU’s MDR regulations for cybersecurity
HOUSTON – October, 26 2022 – Velentium, a professional engineering firm that specializes in the design and manufacturing of therapeutic and diagnostic active medical devices, announced today that Director of Human Factors Albert Rodriguez and Director of Product Security Christopher Gates will each host presentations at MD&M Minneapolis held at the Minneapolis Convention Center Nov. 2-3, 2022.
User-Centered Design for MedTech Devices: Lessons Learned in Human Factors
“I am honored to be welcomed as a speaker at MD&M Minneapolis,” said Rodriguez. “The conference brings together medical manufacturers, industry experts, thought leaders, and academics to solve challenges in medical technology. One of those challenges is our approach to user-centered design (UCD). While UCD may not always be as intuitive or universal as the design team may have assumed, there are principles that can reduce support costs, increase market penetration, reduce project delays or regulatory challenges and even mitigate recalls.”
Rodriguez’s presentation on day one of the conference focuses on how achieving user-centered design (UCD) in practice is rarely as straightforward as it seems. In his talk, Rodriguez will provide an overview of UCD principles; explain how, when, and why to introduce those principles into existing design processes; and show how and how not to translate outcomes from UCD activities into product requirements and features. This presentation will be held in Room 101 H on Nov. 2 from 11-11:45 a.m. CST.
Aligning FDA Expectations and EU's MDR Regulations for Cybersecurity
“It is satisfying to speak at another MD&M conference on MedTech security,” said Gates. “As cybersecurity requirements in premarket submissions change, it is important to know the deliverables and processes necessary to create secure medical device systems efficiently and cost-effectively.”
In Gates’ presentation on day two, he will discuss the new medical device cybersecurity laws and regulatory requirements and review the new manufacturer's activities expected by the FDA, including the expected 41 cybersecurity deliverables. Importantly, Gates will focus on how to add cybersecurity processes to the development lifecycle that will satisfy the FDA and secure a medical device system without generating massive cost burdens or development delays. This session will be held on Nov. 3 in the Tech Theater on the main expo floor from 12:30-1:15 p.m. CST.
Velentium in Minneapolis
With Minneapolis being the undisputed center of MedTech innovation in the United States, and arguably the world, it is the perfect place for MD&M to hold one of its conferences. The region’s overt contributions to the MedTech industry are unmatched. With an interest in changing lives for the better, and as a member of Medical Alley’s MedTech Association, Velentium is honored to be a part of the industry conversation at MD&M Minneapolis this year.
Velentium’s presence at the event will be multi-faceted, with not only the presentations previously mentioned but also with representation at a booth on the floor where attendees can learn more about the business, its capabilities, partnerships, and previous projects.
Velentium is always looking to partner with organizations that are in the business of changing lives. For any company that is facing concerns in cybersecurity, design challenges, software development & quality, mobile apps & cloud integrations, contract manufacturing or something similar, Velentium wants to help. A Houston-based professional engineering firm, Velentium specializes in design & development solutions where the science is near-impossible. Velentium has a team of world-class cybersecurity experts, and software, electrical, and mechanical engineers that have decades of know-how and skills in each of their respective fields. Velentium brings each project together with some of the best systems engineering in the industry. The process followed throughout the project is fine-tuned to fit each client’s specific needs to ultimately help them achieve their business goals.
Velentium loves projects that many MedTech engineering & consulting firms and contract manufacturers won't touch. Projects involving class IIIs, active implantables, neuromodulation and DBS, SaMD, complex integrated systems with brains and comms, and more are all within the scope of what Velentium can do. If any business is interested in working with world-class experts on a life-changing project, come visit the Velentium booth and talk with a team member at the event. Velentium can be found at Booth #2911.
After MD&M Minneapolis, Velentium has a full slate of trade show appearances on the calendar into 2023. To reserve a meeting with the team at any of the following conferences, email this inbox. Velentium’s experts are eager to foster new connections and cultivate future partnerships to change lives for a better world.
- MD&M Minneapolis – Nov. 2-3, Minneapolis, MN
- Medica/Compamed – Nov. 14-17, Dusseldorf, Germany
- BIOMEDevice Silicon Valley – Nov. 29-30, Santa Clara, CA
- NANS – Jan. 12-15, 2023, Las Vegas, NV
- MD&M West – Feb. 7-9, 2023, Anaheim, CA
- LSI Emerging MedTech Summit – March 20-23, 2023, Dana Point, CA
- MedTech Strategist – April 25-27, 2023, Dublin, Ireland
- True Quality – June 2023, TBA
- BIOMEDevice Boston – Sep. 20-21, 2023, Boston, MA
Velentium is a Houston-based professional engineering firm specializing in the end-to-end design, development, manufacturing and post-market support of therapeutic and diagnostic active medical devices. The company's core competencies include active implantable medical devices, systems engineering, firmware & software, cybersecurity, mobile & cloud, electrical & mechanical engineering, human factors & usability, automated test systems, and CGMP manufacturing. With customers all over the world, Velentium has experience working with all sizes of clients, ranging from startups seeking seed funding to established Fortune 500 companies.